While the three biotech penny stocks highlighted in today’s article are risky, each of these under-$5 plays has earned a Moderate or Strong Buy consensus rating from analysts – and each boasts significant upside potential attributable in large part to COVID-19. For these three compelling biotech penny stocks, CLICK HERE.